GLP-1 Peptide Industry Data: Market Trends, Brand Comparison, and Product Analysis
Title: GLP-1 Peptide Industry Data: Market Trends, Brand Comparison, and Product Analysis Abstract: The GLP-1 peptide market is projected to exceed $56 billion by 2030 (CAGR 12.5%), driven by obesity and diabetes therapeutics. This analysis compares leading brands (e.g., Novo Nordisk’s Ozempic, Eli Lilly’s Mounjaro) across purity (>99%), half-life, and efficacy. Key technical advantages include sustained glucose control; limitations involve gastrointestinal side effects. Product parameters (dosage, storage at 2–8°C) and logistics (cold chain compliance) are critical. Industry trends show a shift toward oral formulations and biosimilars. Selection criteria prioritize GMP-certified facilities, third-party HPLC/LC-MS certificates, and regulatory approvals (FDA, EMA). This guide synthesizes market data, brand comparisons, and quality benchmarks for informed sourcing.